Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer

21 Aug 2014

Abstract excerpt

BACKGROUND: PCDH8 is a novel tumor suppressor gene, and frequently inactivated by promoter methylation in human cancers. However, there is little information regarding PCDH8 methylation in non-muscle invasive bladder cancer (NMIBC). The aim of this study was to investigate the methylation status of PCDH8 in NMIBC and its clinical significance. METHODS: The methylation status of PCDH8 in 233 NMIBC tissues and 43...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Epigenetics and DNA Methylation
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25927589
DOI: 10.1186/s13046-014-0068-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancerPMID 25927589Read ↗

Clinical and Prognostic Significance of Protocadherin-10 (PCDH10) Promoter Methylation in Bladder CancerSemantic proximity Read ↗

Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancerSemantic proximity Read ↗

Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non Muscle Invasive Bladder CancerSemantic proximity Read ↗

Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patientsSemantic proximity Read ↗

Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancerSemantic proximity Read ↗

Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.Semantic proximity Read ↗

p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder CancerSemantic proximity Read ↗

High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphomaSemantic proximity Read ↗

Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder CancerSemantic proximity Read ↗

Clinical Significance of the Methylated Cytosine-Phosphate-Guanine Sites of Protocadherin-10 Promoter for Evaluating the Prognosis of Gastric CancerSemantic proximity Read ↗

HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.